文献速递血液净化与透析

老年血液透析血管通路选择:成本效果分析

Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-05-18

该研究采用Markov模型模拟初始血液透析并留置中心静脉导管的老年患者,比较动静脉内瘘、动静脉移植物或继续使用导管三种策略的成本效果。结果显示,动静脉内瘘在所有年龄和预期寿命组中均较继续使用导管具有成本效果,但85-89岁最低预期寿命四分位组除外;在65-69岁组中,内瘘在所有预期寿命四分位组均较移植物更具成本效果。

要点

  • 老年患者透析后1月内放置动静脉内瘘的成本效果随年龄增长和预期寿命降低而减弱。
  • 85-89岁且预期寿命处于最低四分位者,内瘘较继续使用导管无成本效果。
  • 65-69岁组中,内瘘在所有预期寿命四分位均较移植物更具成本效果。

核心结论

  • 在老年患者中,透析后第一个月内放置动静脉内瘘的成本效果随年龄增长和预期寿命降低而减弱,对于预期寿命最有限者并非最具成本效果的选项。

研究设计与样本

  • 采用假设性队列构建Markov模型,模拟初始血液透析并留置中心静脉导管的患者,比较动静脉内瘘、动静脉移植物或继续使用导管三种策略。
  • 成本、效用和转移概率来自现有文献,按年龄组(65-69、70-74、75-79、80-84、85-89岁)和预期寿命四分位进行概率敏感性分析,评估长达5年的成本、质量调整生命月和增量成本效果比。

主要发现

  • 动静脉内瘘策略在所有年龄和预期寿命组中均较继续使用导管具有成本效果,但85-89岁最低预期寿命四分位组除外。
  • 在65-69岁年龄组中,动静脉内瘘策略在所有预期寿命四分位均较动静脉移植物策略更具成本效果。
  • 对于更年长组,策略间成本效果差异减弱,动静脉内瘘策略仅在预期寿命>2年的患者中倾向于具有成本效果。
  • 对于动静脉内瘘策略非成本节省的组,每获得一个质量调整生命月的成本范围为2294至14042美元。

关键数值与推荐

  • 动静脉内瘘与继续使用导管比较:所有年龄和预期寿命组均具成本效果,但85-89岁最低预期寿命四分位组除外。
  • 动静脉内瘘与动静脉移植物比较:65-69岁组所有预期寿命四分位均内瘘更优;更年长组仅预期寿命>2年者内瘘倾向成本效果。
  • 内瘘非成本节省组每获得一个质量调整生命月成本为2294至14042美元。

临床怎么用

  • 老年患者透析后放置动静脉内瘘的决策应结合年龄和预期寿命个体化评估,尤其对高龄且预期寿命有限者。
  • 对于预期寿命>2年的老年患者,动静脉内瘘可能仍具成本效果;对于预期寿命极短者,需权衡内瘘放置的成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Although arteriovenous fistulas have been found to be the most cost-effective form of hemodialysis access, the relative benefits of placing an arteriovenous fistula versus an arteriovenous graft seem to be least certain for older adults and when placed preemptively. However, older adults' life expectancy is heterogeneous, and most patients do not undergo permanent access creation until after dialysis initiation. We evaluated cost-effectiveness of arteriovenous fistula placement after dialysis initiation in older adults as a function of age and life expectancy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using a hypothetical cohort of patients on incident hemodialysis with central venous catheters, we constructed Markov models of three treatment options: (1) arteriovenous fistula placement, (2) arteriovenous graft placement, or (3) continued catheter use. Costs, utilities, and transitional probabilities were derived from existing literature. Probabilistic sensitivity analyses were performed by age group (65-69, 70-74, 75-79, 80-84, and 85-89 years old) and quartile of life expectancy. Costs, quality-adjusted life-months, and incremental cost-effectiveness ratios were evaluated for up to 5 years. RESULTS: The arteriovenous fistula option was cost effective compared with continued catheter use for all age and life expectancy groups, except for 85-89 year olds in the lowest life expectancy quartile. The arteriovenous fistula option was more cost effective than the arteriovenous graft option for all quartiles of life expectancy among the 65- to 69-year-old age group. For older age groups, differences in cost-effectiveness between the strategies were attenuated, and the arteriovenous fistula option tended to only be cost effective in patients with life expectancy >2 years. For groups for which the arteriovenous fistula option was not cost saving, the cost to gain one quality-adjusted life-month ranged from $2294 to $14,042. CONCLUSIONS: Among older adults, the cost-effectiveness of an arteriovenous fistula placed within the first month of dialysis diminishes with increasing age and lower life expectancy and is not the most cost-effective option for those with the most limited life expectancy.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hall RK, Myers ER, Rosas SE, et al. Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis. Clin J Am Soc Nephrol. 2017. PMID: 28522655. doi:10.2215/CJN.11631116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。